TY  - JOUR
AU  - Auriemma, Renata S
AU  - Gahete, Manuel D
AU  - Gatto, Federico
PY  - 2022
DO  - 10.3389/fendo.2022.861230
SN  - 1664-2392
UR  - http://hdl.handle.net/10668/20561
T2  - Frontiers in endocrinology
AB  - Pituitary tumors may exhibit resistance to conventional medical treatments, including somatostatin receptor (SST) ligands (SRLs) and dopamine agonists (DAs) (1, 2). Resistance to medical treatment leads to multi-modal therapies, including surgery and...
LA  - en
PB  - Frontiers Research Foundation
KW  - Adenomas
KW  - Dopamine receptors
KW  - Pituitary
KW  - Resistance
KW  - Somatostatin receptors
KW  - Tumors
KW  - Pituitary neoplasms
KW  - Dopamine agonists
KW  - Receptors, somatostatin
KW  - Pituitary diseases
KW  - Chronic disease
KW  - Prognosis
TI  - Editorial: Resistance to Medical Therapy in Pituitary Tumors.
TY  - research article
VL  - 13
ER  -